Why ovarian cancer gets diagnosed late — and what changes that

You've been bloated for six weeks. Your jeans fit fine but you feel full after half a meal. You've been to the bathroom more than usual. You assumed it was stress, diet, your gut doing something new.

This is not a horror story. It is an account of what ovarian cancer symptoms actually look like — and why the delay from symptom onset to diagnosis averages five months in research studies. The problem isn't that there are no symptoms. The problem is that each one is a perfect decoy for something ordinary.

92%
Five-year survival rate for ovarian cancer caught at Stage I — when it's confined to the ovary. Compare this to 29–46% for Stage III-IV. Early detection is not academic; it is the difference between manageable and devastating
~12 months
Median time from first recognizable symptom to diagnosis in the BEAT Ovarian Cancer Awareness Study — meaning women lived with these symptoms for nearly a year before receiving a diagnosis
19,880
Estimated new ovarian cancer diagnoses in the US annually (ACS 2024 data). It is less common than breast or uterine cancer — but significantly more lethal because of late-stage detection rates

What "the symptoms exist" actually means

The Ovarian Cancer Symptom Index — developed from research by Goff et al. — established four core symptoms associated with ovarian cancer: bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency.

None of these are unusual on their own. The index establishes the clinical threshold this way: symptoms that are new, that occur frequently (more than 12 days per month), and that have been present for less than 12 months (meaning they're new, not a decade-old IBS pattern) represent the flag worth pursuing.

The distinction between ordinary and significant is persistence and change. Bloating you've had every month for years before your period is not the same clinical signal as new bloating that doesn't follow any pattern, doesn't resolve after your period, and is progressively worse. That latter profile is the one that warrants more than a "wait and see."

Research note

The BEAT (Bloating, Eating, Abdominal pain, Trouble with urination) Ovarian Cancer Awareness Study found that 70% of women experienced these symptoms at least five months before their diagnosis — and most had reported them to a physician without follow-up. The authors identified that women themselves often minimized the symptoms, attributing them to IBS, menopause, or stress. Physician response was also variable. The study's implication: patient awareness of the persistent-symptom threshold changes the conversation at the point of care.

Screening — what exists and what doesn't

The honest picture is that there is no recommended routine screening test for average-risk women. The two candidates — CA-125 blood test and transvaginal ultrasound — have both been studied in large trials and found to produce more harm through false positives and unnecessary surgery than benefit through early detection.

This is genuinely frustrating. It is also not the same as saying there is nothing to do. For women at elevated risk, the picture is different.

BRCA1 mutations carry a lifetime ovarian cancer risk of 44–46%. BRCA2 mutations carry approximately 17–23%. For women who know they carry either mutation, intensive monitoring with six-monthly transvaginal ultrasound and CA-125 is recommended — alongside a serious conversation with a genetic counselor about risk-reducing salpingo-oophorectomy (surgical removal), typically considered after childbearing is complete.

Family history (first-degree relative with ovarian cancer) also raises risk meaningfully and warrants a discussion with a gynecologist about monitoring beyond standard care.

March 2026: the FDA approved Lifyorli (relacorilant in combination with nab-paclitaxel) for platinum-resistant ovarian cancer — meaning cancer that has stopped responding to standard chemotherapy. This is not a screening development, but it matters for women navigating advanced disease and is a meaningful expansion of available treatment options.

What to tell your doctor

🦺

On being taken seriously

Research consistently shows that women's gastrointestinal and pelvic symptoms are more frequently attributed to psychosomatic causes than equivalent symptoms in men. If your concern about persistent symptoms is being attributed to stress or IBS without investigation, you have the right to ask for imaging or a gynecology referral. "I'd like to rule out ovarian pathology" is a reasonable request that your physician should document and respond to, not dismiss.

Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

  1. Goff BA, et al. Development of an ovarian cancer symptom index. Cancer. 2007;109(2):221–227. doi:10.1002/cncr.22408
  2. Moyer VA; US Preventive Services Task Force. Screening for ovarian cancer. Annals of Internal Medicine. 2012;157(12):900–904.
  3. Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–2416. doi:10.1001/jama.2017.7112
  4. FDA. Approval of Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer. March 25, 2026.
  5. American Cancer Society. Cancer Facts and Figures 2024. Atlanta: American Cancer Society; 2024.